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ABSTRACT

Human Immunodeficiency Virus (HIV) has become a global pandemic with at least 25 million
deaths and no cure. One of the most important targets to inhibit this virus is HIV-1 protease
(PR), which is required to cleave the viral proteins needed for maturation of the virus after it
invades and replicates in the host cell. There are nine protease inhibitors that are used in AIDS
treatment. The virus loses susceptibility to these inhibitors by drug resistance due to mutations.
The goal of the project is to examine the highly drug resistant HIV PR P51 in its complex with
inhibitors. In this experiment we expressed and purified HIV PR P51 protein. We performed
protein crystallization with inhibitors Tipranavir, Amprenavir, Darunavir, and Saquinavir to
obtain the structure of the protease and the inhibitors in their complexes. Future analysis of the
crystal structures will help with the development of successful therapeutic inhibitors.
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1
Introduction
The number of people currently living with Human Immunodeficiency Virus (HIV) has
increased drastically since the virus was first recognized (4). UNAIDS (Joint United Nations
Programme on HIV/AIDS), WHO (World Health Organization), and UNICEF (United Nations
Children’s Fund) have estimated at least 30.6 million adults and 3.4 million children who are
infected with HIV at the end of the year of 2012 (17). The development of Highly Active
Antiretroviral Therapy (HAART) using a combination of different antiviral drugs to suppress
HIV over the years has helped to reduce the effects of the disease on the immune system but still
there is no cure (2). Even with the drug therapies available today, multidrug resistance is
becoming more of an issue. HIV protease (PR) is an enzyme that is vital to the functioning of
HIV (6). PR’s catalytic role is an important step in HIV replication because it generates mature
infectious viral particles by cleaving viral polyproteins Gag and Gag-Pol (Figure 1) (6). Gag is
cleaved into three large protein’s called p24, p17, p7 and small proteins called p6, p2, and p1
(6).The large proteins contribute to the structure of the virion and RNA packing and the function
of the small proteins are uncertain (6). Gag- pol is cleaved into protease (PR), reverse
transcriptase (RT), and integrase (IN) (6). Consequently, HIV protease has been a valuable
therapeutic target for HIV/AIDS structure-based drug design for decades (16).
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Figure 1. HIV-1 protease and Gag and Gag-Pol with cleavage sites.

Figure 1. This figure shows the HIV-1 protease at a 180 degree angle (B) and gag and gag-pol
genes that are cleaved by HIV-1 protease and at what site these proteins are cleaved (C). [6]
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Human Immunodeficiency Virus
Human Immunodeficiency Virus (HIV) is an enveloped retrovirus that leads to the
development of Autoimmune Deficiency Syndrome (AIDS) (16). HIV-1 virus can damage the
immune system by depleting the CD4+ T cells, also known as T helper cells (13). In order for
HIV to successfully destroy the T helper cells, it must first invade the body successfully and
undergoes replication. HIV’s mode of transmission is through sexual, percutaneous, and
perinatal methods but the most common method is sexual contact (9). Some examples of
behaviors that can cause the viral infection come from contact with bodily fluids are sharing of
needles, syringes, and being born to an infected mother (9). Once it has entered the bloodstream
it can begin its phase of replication and destruction of T helper cells. HIV binds to the CD4 and
CXCR5 receptors and fuses its envelope with the host cell cellular membrane and liberates its
envelope. After that, the proteins and nucleic acids that compose the virus are allowed to enter
into the cytoplasm of the cell (8). Then, the ribonucleic acid (RNA) is reverse transcribed into
double stranded deoxyribonucleic acid (DNA). The DNA is then integrated into the host DNA
via viral integrase (8). The DNA is transcribed into new viral RNA and new viral proteins are
made. The proteins with the RNA assemble around the host membrane to bud forming the
mature viral particle (8). The new viral particle then continuously invades the host cells and
multiplies, taking over the host cell machinery (Figure 2).
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Figure 2. HIV-1 Life Cycle in Host Cell.

Figure 2. Representation of HIV-1 virus life cycle in the host cell. Positive (+) and negative (-) cellular
factors are indicated next to the step in viral replication that they affect. (13)
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HIV-1 Virion Structure
The HIV-1 virion shown in Figure 3 (15) is a spherical and compact structure. The viral
envelope is the outmost part which is a plasma membrane of host-cell origin. On this membrane
is the envelope which includes the surface unit glycoprotein (SU) gp120 and transmembrane
envelope (TM) gp41. The viral structure proteins are referred to as Gag proteins: the matrix
protein (MA) is located under the envelope and encases the capsid shell; two copies of genomic
single-stranded RNA are enclosed by the conical capsid which comprising of capsid protein
(CA); the single-strand RNA is tightly bound to the nucleocapsid proteins (NC) (5). Associated
with the NC and RNA within the capsid are the Pol gene encoded viral-specific enzymes
including the protease (PR), RNA polymerase (RT), integrase (IN) and RNase H (RH). The virus
particles also package the accessory proteins, Nef, Vif, and Vpr while the other three additional
accessory proteins Rev, Tat and Vpu which function in the host cell do not appear in the virions
(15).
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Figure 3. HIV-1 structure and structural proteins.

Figure 3. This represents the HIV-1 virion structure and the structural proteins. The
structural protein include Surface unit glycoprotein (SU)gp120, transmembrane
envelope (TM) gp41, the matrix protein (MA) capsid protein (CA), nucleocapsid
proteins (NC), protease (PR), RNA polymerase (RT), integrase (IN) and RNase H
(RH), accessory proteins ( Nef, Vif, Vpr, Rev, Tat and Vpu). (Turner, et. al)
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HIV Protease
Protease is an enzyme that catalyzes the cleavage of peptide bonds between amino acids
of a protein (6). HIV-1 protease functions by cleaving peptide bonds of HIV-1 viral proteins.
HIV-1 protease is encoded on the 5’ end of the 99 amino acid HIV-1 gene gag-pol (6). The
protease cleaves amino acid sequences in the Gag and Gag-Pol polyproteins, which is necessary
in order for the maturation and replication of virion (6, 8). Lack of an efficient protease causes
the development of immature, noninfectious viral particles, which is one of the reasons that the
protease is a target for inhibition with many synthetic inhibitors (6). There are ten inhibitors of
HIV protease (PR) that are used in antiviral therapy. They are amprenavir (APV), atazanavir,
indinavir, lopinavir, nelfinavir, ritonavir, nelfinavir, saquinavir (SQV), tipranavir(TPV), and
darunavir (DRV) (6). A protease inhibitor (PI) is designed to inhibit HIV PR based on its
structure, mainly its active site (16). These inhibitors interact competitively with the active site
and the transition state of the enzyme reaction, inactivating the enzyme function. PIs are very
effective in HAART treatment for AIDS and are usually used in a combination of three different
antiviral drugs.
Drug Resistance
There is currently no cure for the HIV infection, but there are treatments currently
available to slow the progression of the disease. Creation of therapeutic interventions like
inhibitors has proven to be successful but have been succeeded by resistance. The creation of
these antiviral inhibitors was promising due to the knowledge of the crystal structure of HIV
protease and how it binds substrate like inhibitors. One such inhibitor, darunavir (DRV), which
is a structure-based designed nonpeptidic ligand (10), has been widely used for the treatment of
drug-naïve and multidrug-resistant HIV-1 infected patients and was the most recently approved
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PI for drug resistant infections (18-20). Similar to other retroviral polymerases, HIV RT does not
have a proofreading function and thus increases the mutational rates of the virus. The emergence
of resistance to HIV-1 PIs is associated with the appearance of amino acid substitution mutations
in the viral protease gene (Table 1). The mechanism for the development of resistance to PIs is
quite complicated (5). The locations of PI-resistant mutations vary from substrate/inhibitor
binding site, dimer interface, and flap region to surface of PR (Figure 4)(1). One explanation is
that the residues near the active site can directly interfere with the binding of the inhibitor to the
enzyme by modifying its specificity and/or affinity (20). Another cause for those mutations
which do not directly change the shape or property of the binding cavity is that they may affect
the efficiency of catalysis and the stability of the PR, or influence enzyme active site via longrange structural perturbations (11). To date, among the 99 amino acid residues of the protease, 25
or more have been implicated in resistance to PIs (Figure 5) (12).

Table 1. HIV-1 Protease Inhibitors and the Related Drug Resistance Mutations

Table 1. This table represents known antiviral data for clinical protease inhibitors and their drug
resistant mutations. Bold red indicates phenotypic evidence for reduced susceptibility in vitro and
clinical evidence for reduced virological response. Underlined bold red indicates drugs that should
be contraindicated when the mutation is present. ((http://hivdb.stanford.edu/cgi-bin/PIResiNote.cgi,
HIV Drug Resistance Database, Stanford University)
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Figure 4. Structure of HIV-1 protease in dimer form.

Figure 4. Structure of dimer of HIV-1 protease. Locations of 14 amino acid substitutions in the dimer structure
and a list of substitutions in HIV PR P51 (Figure provided by Ying Zhang).

Figure 5. Crystal Structure of HIV-1 PR Dimer with Sites of Drug Mutation.

Figure 5. Shaded regions in monomer indicate the secondary structure of the dimeric enzyme. The
three mutations Q7K, L33I, and L63I in PR to prevent its intrinsic autoproteolysis and the active site
aspartic acid residues of each monomer are shown in a stick representation. Positions of drug-resistant
mutations are indicated in blue. (12)
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It has been reported that substitution of a variety of amino acids were related to HIV-1
resistance to DRV although it has a potent genetic barrier to the development of HIV-1
resistance and effectively inhibits PR enzymatic activity and dimerization (5). Hence, to further
design more effective anti-HIV-1 drugs, highly DRV-resistant HIV-1 variants were acquired to
elucidate the mechanism for development of DRV resistance. In Koh’s lab, in vitro selection of a
mixture of 8 highly DRV-susceptible HIV-1 clinical isolates (HIV-1MIX), which contain 9 to
14 PI-resistant mutations, was conducted to be propagated and thus a series of highly DRVresistant viral populations were produced at different passages (10). The population at passage 51
(HIV-1MIXP51) replicated well at the concentration of 5 μM DRV containing 14 amino acid
substitutions related to HIV-1 resistance (10). HIV-1MIXP51 has shown a high resistance to
amprenavir, indinavir, nelfinavir, ritonavir, lopinavir and atazanavir in addition to darunavir (all
with EC50s > 1 μM) and moderate resistance to saquinavir (33 fold increase in EC50) and
tipranavir (18 fold increase in EC50) (6). Meanwhile, in the Louis’s lab, they assayed the
inhibition of protease from HIV-1MIXP51 (P51) and the precursor flanked by the transframe
region (TRF) to its N-terminus (7). It has also shown that the binding constant KL of DRV for
PR-P51 was about 7400 fold higher than for wild type protease while the IC50 of TFR- PR-P51 is
over 150 fold to TFR-PR. Hence, we are trying to study the crystal structures of HIV PR P51
with DRV, APV, SQV and TPV (molecular structures, Figure 6). Crystallizations of these four
complexes are performed as the basis for structural study.
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Figure 6. Molecular Structure of SQV, APV, DRV, and TPV

Amprenavir

Figure 6. This image shows the molecular structure of the 4 clinical inhibitors for HIV-1
protease that were used in this study.

Experimental Methods and Materials
Protein Expression
In order to express the HIV-1 protease mutant P51, a bacterium is used and the gene of
interest is inserted into the plasmid. In this experiment, E-coli bacteria were used as the
expression system and pET11A plasmid was used. It contains approximately 5,000-6,000 base
pairs (bp) and is ampicillin resistant. In order to express the protein, an expression system was
created. The large broth media was created by adding 25 g of Luria broth (solid) to 1 L of
distilled water. Mixture was stirred and carbenicillin (CBN) with a final concentration of 100
µg/ml was added to mixture. 25 ml Luria broth was created and CBN with a final concentration
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of 100 µg/ml was added to mixture. The cells were inoculated into smaller broth mixture and
allowed to grow at 37ºC overnight. After stirring overnight, starter culture was added to larger
broth 1 L solution and allowed to shake until optical density (OD) value reached approximately
0.5-0.6. Isopropylthio-β-galactoside (IPTG) with a final concentration of 2mM was added to
induce protein expression for approximately 3-4 hours. Mixture was then centrifuged at 6,000
rpm for 20 minutes and pellet was retrieved. Pellet was resuspended twice in 50 ml of TE Buffer
(50mM Tris and 10mM EDTA in 1L of dH2O) and centrifuged at 6,000 rpm for 20 minutes.
Pellet was resuspended in a 60 ml of TE solution (TE buffer volume is 20 times ml of the cell
weight) to prevent desired protein degradation and 0.1 mg/ml lysozyme to break the cell wall of
the bacteria. Solution was sonicated for 5-6 cycles and centrifuged at 12,000 rpm for 20 minutes
to spin down the inclusion body. Solution was resuspended in Triton Buffer (1% Triton and 2M
urea in TE) centrifuged at 12,000 rpm for 20 minutes, pellet was retrieved, and step was repeated
again. Solution was resuspended in 8 M guanidine hydrogen chloride and TE buffer. Solution
was centrifuged at 12,000 rpm for 20 minutes and supernatant with crude protein was obtained.
Protein Purification
The proteins were purified first by the gel filtration method using size exclusion column
(Hiload 26/30, Superdex 75 preparative grade ÄTKA prime) with washing solution of 50mM
Tris, 5mM of EDTA, and 3M of Gu•HCl. And further purification was operated on HPLC by a
gradient washout of 0.05% TFA in H2O and 0.05% TFA in CH3CN (340 µL TFA in 1L of
distilled water). The HPLC products of protein was then placed in a dialysis cassette with 10,000
molecular weight cutoff (MWCO) and allowed to undergo dialysis in two steps: first in buffer A
of 25 mM formic acid to eliminate the acetonitrile and buffer B of 50 mM NaOAc to refold the
protease.
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Protein Crystallization
The crystals of HIV-1 protease P51 and D25N mutant and TPV, SQV, DRV, and APV
were grown using the hanging drop vapor diffusion procedure with a 1:20 and 1:40 ratio of
inhibitor to protein. The hanging drop method entails the addition of a droplet (1 µL) of the
purified protease and inhibitor complex, precipitant, buffer, and additives to a cover slip which is
inverted onto a well with similar conditions. The drop is allowed to sit overnight at room
temperature to allow for precipitation. The conditions under which these protein crystals were
grown contain Potassium sodium tartrate, PEG 8000, HEPES, 0.1 M sodium cacodylate in
different pH, 0.1 M ZnAc2 and 0.1 M CaAc2. Crystals were then frozen, mounted in
cryptoprotector with 25% glycerol of the mother liquid, and sent for X-ray crystallography
analysis at the Southeast Regional Collaborative Access Team X-ray beamlines of the Advanced
Photon Source, Argonne National Laboratory, Argonne, IL.
Measurement of Protease Activity and Inhibition
The TPV inhibition constant for P51 was tried to be measured using a fluorescence assay
with the substrate Abz-Thr-Ile-Nle-pNO2Phe-Gln-Arg-NH2 (where pNO2Phe is para-nitrophenylalanine, Nle is norleucine and Abz is anthranilic acid) (Bachem Bioscience Inc., King of
Prussia, PA), which is based on the p2/NC cleavage site of the viral polyprotein. 10 μl PRP51
with a concentration of about 50 μM with a gradient concentration of TPV was mixed with 100
μl of reaction buffer [100 mM MES (4-morpholineethanesulfonic acid), pH 5.6, 400 mM NaCl, 1
mM ethylenediaminetetraacetic acid, and 5% glycerol] at 26 ˚C. The reaction was initiated by
adding substrate of a final concentration of 72 μM by monitoring the increase in fluorescence
over 5 min using an excitation wavelength of 340 nm and emission wavelength of 420 nm
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(pNO2Phe as quencher-fluorescent acceptor; Abz as fluorescent donor) with a POLARstar
OPTIMA 96-well microplate instrument (BMC Labtech).

Results
Expression of HIV Protease P51 Mutant
Expression had to be repeated since cells were not obtained during the first expression
phase. When the cells were transferred to a larger broth, they double in number every 60
minutes. Pellet was successfully centrifuged and approximately 3 grams of cells were grown.

Purification of HIV Protease Mutant P51
HIV PR p51 was purified using High Performance Liquid Chromatography (HPLC) and Gel
Filtration (Figure . We obtained about 1.2 mg/ml for monomer.

Crystallization of HIV Protease P51 Mutant with Inhibitors
Protein PR p51 D25N was used because the D25N mutation allowed for deactivation of
protein activity. We did not try P51 without the D25N mutation. The concentration of protein
that was used was 1.2 mg/ml. The protein crystals that were grown were PR p51 and TPV, PR
p51 and APV, PR P51 and SQV, and PR p51 and DRV. In each condition, dH20 was added until
final concentration of the mother liquid equaled 600 µl. One condition in which PR p51 and
APV(protein-inhibitor ratio of 1:20) crystals grew were2M Potassium sodium (KNA)tartrate, 0.1
Sodium cacodylate (NaCaco dylate) pH 6.6, HEPES,15% PEG 8000, 0.02M CaAc2, and dH2O.
Another condition in which PR p51 and APV (ratio 1:20) crystals grew was 2M KNA tartrate,0.1
M NaCaco dylate pH 6.0, HEPES, 20% PEG 8000, 0.02M CaAc2, and dH2O.The crystals were
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medium sized in both conditions. For PR p51 and APV with a protein-inhibitor ratio of 1:40, one
condition in which crystals grew was 2M KNA tartrate, 0.1 NaCaco dylate pH 6.6, 15% PEG
8000, HEPES, 0.02 M CaAc2, and dH2O. Another condition in which crystals grew with PR p51
and APV (ratio 1:40) was 2M KNA tartrate, 0.1 NaCaco dylate pH 6.0, 18% PEG 8000, HEPES,
0.02 M CaAc2, and dH2O. For PR p51 and DRV (ratio 1:20), one condition in which crystals
grew was 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.6, HEPES, 15% PEG 8000, 0.02M
ZnAc2, and dH2O (Image 1).The crystals that were grown were big in size. For PR p51 and SQV
(ratio 1:20), one condition in which crystals grew was 2M KNA tartrate, 0.1 M NaCaco dylate
pH 6.0, HEPES, 20% PEG 8000, 0.02M ZnAc2, and dH2O. Another condition in which PR p51
and SQV (ratio 1:20) grew crystals was 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.0, HEPES,
10% PEG 8000, 0.02M CaAc2, and dH2O. When growing PR p51 and SQV (ratio 1:40) under
the following conditions 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.0, HEPES, 15% PEG
8000, 0.02M ZnAc2, and dH2O, crystals grew. These crystals were medium sized. Lastly, for PR
p51 and TPV, one condition in which crystals grew was 2M KNA tartrate, 0.1 M NaCaco dylate
pH 6.0, HEPES, 20% PEG 8000, 0.02M ZnAc2, and dH2O (Image 2). Very small sized crystals
formed. All crystals listed above were sent to Argonne National Laboratories for diffraction data
collection at the Southeast Regional Collaborative Access Team X-ray beamlines. Processing
and analysis of the X-ray crystallographic data is in progress.

Enzyme activity and inhibition
The enzyme activity of the protease was tested and there was no activity. Inhibition of the
enzyme could not be measured. The concentration used was 1.29 mg/ml. For inhibition constant
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measurement, we did not obtain any result due the poor activity of P51. The protein did not show
sufficient activity. The expression will need to be repeated with fresh cells and or plasmid DNA.

Discussion
Antiviral drugs have been successful when it comes to reducing the effects of the HIV
virus. With the development of drug resistance the virus continues to function and compromise
the immune system of HIV/AIDS patients. HIV PR p51 (51 serial passages/ stages) was used in
this study because it is one of many mutants that are extremely resistant to drug therapy for HIV.
Studying HIV PR P51 in the complex with inhibitors can lead to the development of successful
therapeutic agents. To analyze, the complex we expressed and purified the protein and grew
crystals to get its crystalline structure. HIV PR P51 was expressed and purified successfully and
protein crystals were grown of PR p51with 4 different inhibitors (TPV, SQV, DRV, and
APV).PR p51 and TPV crystals were very small. PR p51 and SQV crystals were good medium
sized crystals. PR p51 and APV crystals were also good medium sized crystals. PR p51 and
DRV crystals were good and large in size. Enzyme activity and inhibition didn’t turn out as
planned because the activity of p51 was poor. Therefore we could not measure the inhibition of
the enzyme. The next step in research would be to redo the experiment with fresh cells or
plasmid DNA to determine the inhibition constant measurement of the proteinP51. This research
project is a portion of a bigger research project that is currently being conducted. The data
obtained will help with the creation of new and successful antiviral drugs against HIV and it will
also help better understand the mechanism and molecular origin of drug resistance.
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Figure 7. HIV-1 PR p51 Gel Filtration Results

Figure 7. This image represents the results we obtained from gel filtration. The high
peak represents the purified protein PR p51 and D25N that we obtained.
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Figure 8. PR p51 and APV crystals.

Figure 8. This image shows PR p51 and APV (protein-inhibitor ratio 1:20) crystals that grew
under the following conditions: 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.0, HEPES, 20%
PEG 8000, 0.02M ZnAc2, and dH2O.

Figure 9. PR p51 with DRV crystals

Figure 9. Picture of crystals grown for PR p51 and DRV (protein-inhibitor ratio 1:20). The
conditions in which these crystals were grown are 2M KNA tartrate, 0.1 M NaCaco dylate pH
6.6, HEPES, 15% PEG 8000, 0.02M ZnAc2, and dH2O.
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Figure 10. PR p51 and SQV crystals.

Figure 10. This figure represents crystals from PR p51 and SQV (ratio 1:20) which grew
under the following conditions: 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.0, HEPES, 10%
PEG 8000, 0.02M CaAc2, and dH2O.

Figure 11. PR p51 and TPV crystals

Figure 11. This photo represents PR p51 and TPV (ratio 1:20) crystals grown under the
following conditions: 2M KNA tartrate, 0.1 M NaCaco dylate pH 6.0, HEPES, 20%
PEG 8000, 0.02M ZnAc2, and dH2O.
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